Celgene Corporation (CELG): Today's Featured Health Care Winner

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

Celgene Corporation ( CELG) pushed the Health Care sector higher today making it today's featured health care winner. The sector as a whole closed the day up 1.1%. By the end of trading, Celgene Corporation rose $1.93 (1.3%) to $148.79 on average volume. Throughout the day, 2,427,938 shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2,965,400 shares. The stock ranged in a price between $147.19-$149.92 after having opened the day at $148.18 as compared to the previous trading day's close of $146.86. Other companies within the Health Care sector that increased today were: ZELTIQ Aesthetics ( ZLTQ), up 40.2%, Zalicus ( ZLCS), up 30.9%, Biocryst Pharmaceuticals ( BCRX), up 21.1% and Anika Therapeutics ( ANIK), up 20.9%.

Celgene Corporation, a biopharmaceutical company, discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $60.6 billion and is part of the drugs industry. Shares are up 87.2% year to date as of the close of trading on Wednesday. Currently there are 21 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, growth in earnings per share, increase in net income, notable return on equity and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results.

On the negative front, Mast Therapeutics ( MSTX), down 38.6%, Medical Action Industries ( MDCI), down 32.1%, Stereotaxis ( STXS), down 19.9% and Reliv' International ( RELV), down 16.7% , were all laggards within the health care sector with Arena Pharmaceuticals ( ARNA) being today's health care sector laggard.

For investors not wanting singular stock exposure, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

3x UPSIDE POTENTIAL: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

null

More from Markets

Global Stocks Slide as Trump's New Trade War Salvo Ignites Fresh Concern

Global Stocks Slide as Trump's New Trade War Salvo Ignites Fresh Concern

Ackman Investment Buoys Lowe's; DraftKings Responds to FanDuel Merger -- ICYMI

Ackman Investment Buoys Lowe's; DraftKings Responds to FanDuel Merger -- ICYMI

Replay: Jim Cramer on the Markets, Tiffany, Micron Technology and Union Pacific

Replay: Jim Cramer on the Markets, Tiffany, Micron Technology and Union Pacific

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market

Carnival CEO Arnold Donald: China Will Become the Largest Cruise Market

Red Robin Slumps After Earnings Miss

Red Robin Slumps After Earnings Miss